Ann: Kazia presents to Bell Potter Healthcare Conference, page-9

Great point. I vaguely recall (and someone correct me if I am wrong), at the time when JG announced the GBM Agile participation, one of the advantages of the trials was that the sponsors of the trials were able to submit data to the FDA on a rolling basis, rather than wait until the end of the trial. I am certain JG wrote or mentioned this advantage. What is happening with these trails is totally contrary to these statements.